2.840EUR+5.19%Mkt Cap: 197.46M EURP/E: —Last update: 2026-06-01
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The compa…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap197.46M EUR
Enterprise Value96.78M EUR
Revenue (TTM)5.41M EUR
Gross Profit2.74M EUR
Net Income (TTM)-41.79M EUR
Revenue/Share0.1160 EUR
Last Price2.840 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees137
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINNL0015000HT4
Valuation
P/E (Trailing)—
P/E (Forward)-5.07
PEG—
EV/EBITDA-2.40
EV/Revenue17.88
P/S34.67
P/B2.73
EPS (TTM)-0.90
EPS (Forward)-0.53
52W Range
2.41013% of range5.770
52W High5.770 EUR
52W Low2.410 EUR
Profitability
Gross Margin72.51%
Oper. Margin-494.49%
EBITDA Margin0.00%
Profit Margin-1105.48%
ROE-75.54%
ROA-49.42%
Growth
Revenue Growth176.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.07M EUR
CapEx (TTM)432.00K EUR
FCF Margin-439.37%
FCF Yield-12.05%
Net Debt-54.45M EUR
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity0.25
Current Ratio6.67
Quick Ratio6.40
Book Value/Sh0.9880 EUR
Cash/Share1.216 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)9.440 EUR
Target Range8.100 EUR – 11.00 EUR
# Analysts5
Ownership
Shares Out.69.53M
Float43.65M
Insiders28.48%
Institutions23.84%
Technical
SMA 502.996 (-5.2%)
SMA 2004.124 (-31.1%)
Beta0.85
S&P 52W Chg27.94%
Avg Vol (30d)202.94K
Avg Vol (10d)159.31K
Technical Indicators
RSI (14)39.9
MACD-0.0549
MACD Signal-0.0722
MACD Hist.+0.0173
BB Upper2.963 EUR
BB Middle2.774 EUR
BB Lower2.585 EUR
BB Width13.62%
ATR (14)0.1359 EUR
Vol Ratio (20d)1.11x